Hot Pursuit     23-Jan-25
Alivus Life jumps after Q3 PAT climbs 15% YoY to Rs 137 cr
Alivus Life Sciences rallied 4.95% to Rs 1,178.25 after the company’s consolidated revenue jumped 15.33% to Rs 136.96 crore on 12.05% increase in revenue from operations to Rs 641.84 crore in Q3 FY25 over Q3 FY24.
Profit before tax (PBT) climbed 15.22% YoY to Rs 185.14 crore in Q3 FY25.

For Q3FY25, EBITDA was at Rs 200.8 crore, a growth of 15.2% YoY. EBITDA margin stood at 31.3%, up 90 bps YoY.

On segmental front, the revenue from Generic API grew by 16.9% YoY to Rs 596.6 crore in Q3 FY25 while revenue from CDMO declined 14.29% YoY to Rs 30 crore in Q3 FY25.

Yasir Rawjee, MD & CEO, Alivus Life Sciences, said, “The start of the new year marks a notable shift for us as we transition to Alivus Life Sciences. I am pleased to report that our Q3 performance reflects this renewed energy, with growth across both GPL and Non-GPL segments. Geographically, regions like India, Europe, ROW and Japan contributed to the growth.

Alivus Life Sciences (Formerly Glenmark Life Sciences) is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes. It has a diversified portfolio of 161 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan, and the Rest of the World (RoW).

Previous News
  Alivus Life Sciences Ltd leads gainers in 'A' group
 ( Hot Pursuit - 21-Jan-25   12:00 )
  Board of Glenmark Life Sciences recommends interim dividend
 ( Corporate News - 11-Nov-21   10:35 )
  Glenmark Life Sciences to table results
 ( Corporate News - 18-Apr-24   17:37 )
  Glenmark Life Sciences announces board meeting date
 ( Corporate News - 15-Oct-22   10:10 )
  Glenmark Life Sciences renamed as Alivus Life Sciences
 ( Corporate News - 20-Jan-25   10:18 )
  Glenmark Life Sciences fixes record date for interim dividend
 ( Market Beat - Reports 11-Nov-21   09:21 )
  Glenmark Life Sciences IPO subscribed 5.78 times
 ( IPO Centre - IPO News 28-Jul-21   17:50 )
  Glenmark Life Sciences schedules board meeting
 ( Corporate News - 16-Jan-24   12:05 )
  Glenmark Life Sciences director resigns
 ( Corporate News - 22-Apr-24   11:10 )
  Glenmark Life Sciences Ltd leads gainers in 'A' group
 ( Hot Pursuit - 05-Aug-24   12:00 )
  Glenmark Life Sciences announces board meeting date
 ( Corporate News - 17-Oct-24   17:07 )
Other Stories
  Shipping Corp Q3 PAT drops 44% YoY to Rs 76 cr
  08-Feb-25   15:44
  Honeywell Automation PAT rises 3% YoY to Rs 132 cr in Q3
  08-Feb-25   14:35
  Oil India Q3 PAT slides 23% YoY to Rs 1,222 crore
  08-Feb-25   13:01
  Delhivery Q3 PAT climbs 113% YoY to Rs 25 cr
  08-Feb-25   11:56
  LIC Q3 PAT rises 17% YoY to Rs 11,056 cr
  08-Feb-25   11:12
  Fortis Healthcare Q3 PAT climbs 84% YoY to Rs 248 cr
  08-Feb-25   08:59
  Balrampur Chini declines as Q3 PAT slides 23% YoY to Rs 70 crore
  07-Feb-25   16:55
  NOCIL slumps after Q3 PAT slips 57% YoY to Rs 13 crore
  07-Feb-25   16:15
  Bikaji Foods slides as Q3 PAT drops 39% YoY to Rs 29 cr
  07-Feb-25   15:35
  DCX Systems drops after Q3 PAT slides 25% YoY to Rs 10 crore
  07-Feb-25   15:34
Back Top